REFERENCES
- Regier D, Farmer M, Rae D, et al, Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990; 264: 2511–8. [PUBMED], [INFOTRIEVE]
- Kessler R C, McGonagle K A, Zhao S, et al, Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994; 51: 8–19. [PUBMED], [INFOTRIEVE], [CSA]
- Grant B F, Harford T C. Comorbidity between DSM-IV alcohol use disorders and major depression: results of a national survey. Drug Alcohol Depend. 1995; 39: 197–206. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Harwood H. Updating estimates of the economic costs of alcohol abuse in the United States: estimates, update methods, and data [Report prepared by the Lewin Group for the National Institute on Alcohol Abuse and Alcoholism, 2000]
- McGinnis J M, Foege W H. Mortality and morbidity attributable to use of addictive substances in the United States. Proc Assoc Am Physicians. 1999; 111: 109–18. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mokdad A H, Marks J S, Stroup D F, Gerberding J L. Actual causes of death in the United States, 2000. JAMA. 2004; 291: 1238–45. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kessler R, Crum R, Warner L, Nelson C, Schulenberg J, Anthony J. Lifetime co-occurrence of DSM-III alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry. 1997; 54: 313–21. [PUBMED], [INFOTRIEVE], [CSA]
- Finney J W, Hahn A C, Moos R H. The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction. 1996; 91: 1773–96, discussion 1803–20. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Group P MR. Matching alcoholism treatments to client heterogeneity: treatment main effects and matching effects on drinking during treatment. J Stud Alcohol. 1998; 59: 631–9
- Zhang L, Hosoi M, Fukuzawa M, Sun H, Rawlings R R, Weight F F. Distinct molecular basis for differential sensitivity of the serotonin type 3A receptor to ethanol in the absence and presence of agonist. J Biol Chem. 2002; 277: 46256–64. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Weiss F, Porrino L J. Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci. 2002; 22: 3332–7. [PUBMED], [INFOTRIEVE]
- Cami J, Farre M. Drug addiction. N Engl J Med. 2003; 349: 975–86. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Cowen M S, Lawrence A J. The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption. Prog Neuropsychopharmacol Biol Psychiatry. 1999; 23: 1171–212. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Davis K M, Wu J Y. Role of glutamatergic and GABAergic systems in alcoholism. J Biomed Sci. 2001; 8: 7–19. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gianoulakis C. Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism. J Psychiatry Neurosci. 2001; 26: 304–18. [PUBMED], [INFOTRIEVE], [CSA]
- Sullivan J, Sykora K, Schneiderman J, Naranjo C, Sellers E. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989; 84: 1353–7. [PUBMED], [INFOTRIEVE], [CSA]
- Mayo-Smith M F. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. JAMA. 1997; 278: 144–51. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Holbrook A M, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. CMAJ. 1999; 160: 649–55. [PUBMED], [INFOTRIEVE], [CSA]
- Saitz R, Friedman L S, Mayo-Smith M F. Alcohol withdrawal: a nationwide survey of inpatient treatment practices. J Gen Intern Med. 1995; 10: 479–87. [PUBMED], [INFOTRIEVE], [CSA]
- Bastie Y. Suppression by Depakene of epileptic crises caused by withdrawal in alcoholic detoxification. Ann Med Psychol. 1970; 128: 200–4
- Brune F, Busch H. Anticonvulsant-sedative treatment of delirium alcoholism. Q J Stud Alcohol. 1971; 32: 334–42. [PUBMED], [INFOTRIEVE]
- Bjorkqvist S, Isohanni M, Makela R, Malinen L. Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicentre double-blind comparison with placebo. Acta Psychiatr Scand. 1976; 53: 333–42. [PUBMED], [INFOTRIEVE]
- Flygenring J, Hansen J, Holst B, Petersen E, Sorensen A. Treatment of alcohol withdrawal symptoms in hospitalized patients. A randomized, double-blind comparison of carbamazepine (Tegretol) and barbital (Diemal). Acta Psychiatr Scand. 1984; 69: 398–408. [PUBMED], [INFOTRIEVE]
- Malcolm R, Ballenger J C, Sturgis E T, Anton R A. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry. 1989; 146: 617–21. [PUBMED], [INFOTRIEVE]
- Stuppaeck C, Pycha R, Miller C, Whitworth A, Oberbauer H, Fleischhacker W. Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study. Alcohol Alcohol. 1992; 27: 153–8. [PUBMED], [INFOTRIEVE]
- Malcolm R, Myrick H, Roberts J, Wang W, Anton R A. The differential effects of medication on mood, sleep disturbance, and work ability in outpatient alcohol detoxification. Am J Addict. 2002; 11: 141–50. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Reoux J P, Saxon A J, Malte C A, Baer J S, Sloan K L. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res. 2001; 25: 1324–9. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nimmerrichter A A, Walter H, Gutierrez-Lobos K E, Lesch O M. Double-blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal. Alcohol Alcohol. 2002; 37: 67–73. [PUBMED], [INFOTRIEVE]
- Addolorato G, Castelli E, Stefanini G F, et al, An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. GHB Study Group. Alcohol Alcohol. 1996; 31: 341–5. [PUBMED], [INFOTRIEVE]
- Bonnet U, Banger M, Leweke F M, et al, Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial. J Clin Psychopharmacol. 2003; 23: 514–9. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kosten T, O'Connor P G. Management of drug and alcohol withdrawal. N Engl J Med. 2003; 348: 1786–95. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Anton R F, Moak D H, Latham P. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 1995; 19: 92–9. [PUBMED], [INFOTRIEVE], [CSA]
- Bohn M J, Barton B A, Barron K E. Psychometric properties and validity of the Obsessive-Compulsive Drinking Scale. Alcohol Clin Exp Res. 1996; 20: 817–23. [PUBMED], [INFOTRIEVE], [CSA]
- Anton R F. Obsessive-compulsive aspects of craving: development of the Obsessive Compulsive Drinking Scale. Addiction. 2000; 95: S211–7. [PUBMED], [INFOTRIEVE]
- Roberts J S, Anton R F, Latham P K, Moak D H. Factor structure and predictive validity of the Obsessive Compulsive Drinking Scale. Alcohol Clin Exp Res. 1999; 23: 1484–91. [PUBMED], [INFOTRIEVE], [CSA]
- Verheul R, van den, Brink W, Geerlings P. A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol. 1999; 34: 197–222. [PUBMED], [INFOTRIEVE]
- Swift R M. Topiramate for the treatment of alcohol dependence: initiating abstinence. Lancet. 2003; 361: 1666–7. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Volpicelli J R, Alterman A I, Hayashida M, O'Brien C P. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992; 49: 876–80. [PUBMED], [INFOTRIEVE]
- O'Malley S S, Jaffe A J, Chang G, Schottenfeld R S, Meyer R E, Rounsaville B.. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992; 49: 881–7. [PUBMED], [INFOTRIEVE]
- Kranzler H R, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001; 25: 1335–41. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mason B J. Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment. Eur Neuropsychopharmacol. 2003; 13: 469–75. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Krystal J H, Cramer J A, Krol W F, Kirk G F, Rosenheck R A. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001; 345: 1734–9. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fuller R K, Gordis E. Naltrexone treatment for alcohol dependence. N Engl J Med. 2001; 345: 1770–1. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Streeton C, Whelan G.. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol. 2001; 36: 544–52. [PUBMED], [INFOTRIEVE]
- Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2002, CD001867. [CSA]
- Modesto-Lowe V, Van Kirk J. Clinical uses of naltrexone: a review of the evidence. Exp Clin Psychopharmacol. 2002; 10: 213–27. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Group TCSR, Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study. Alcohol Clin Exp Res. 2003; 27: 1123–31. [CROSSREF], [CSA]
- Kranzler H R, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology. 2000; 22: 493–503. [CSA]
- Kranzler H R, Modesto-Lowe V, Nuwayser E S. Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcohol Clin Exp Res. 1998; 22: 1074–9. [PUBMED], [INFOTRIEVE], [CSA]
- Mason B J, Ritvo E C, Morgan R O, et al, A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res. 1994; 18: 1162–7. [PUBMED], [INFOTRIEVE], [CSA]
- Mason B J, Salvato F R, Williams L D, Ritvo E C, Cutler R B. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999; 56: 719–24. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rammes G, Mahal B, Putzke J, et al, The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology. 2001; 40: 749–60. [PUBMED], [INFOTRIEVE], [CSA]
- Mason B J. Acamprosate. Recent Dev Alcohol. 2003; 16: 203–15. [PUBMED], [INFOTRIEVE], [CSA]
- Garbutt J C, West S L, Carey T S, Lohr K N, Crews F T. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA. 1999; 281: 1318–25. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Anton R F, Swift R M. Current pharmacotherapies of alcoholism: a U.S. perspective. Am J Addict. 2003; 12, (suppl 1). S53–68
- Mann K, Lehert P, Morgan M Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res. 2004; 28: 51–63. [PUBMED], [INFOTRIEVE], [CSA]
- Volpicelli J R, Watson N T, King A C, Sherman C E, O'Brien C P. Effect of naltrexone on alcohol “high” in alcoholics. Am J Psychiatry. 1995; 152: 613–5. [PUBMED], [INFOTRIEVE]
- Spanagel R, Zieglgansberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci. 1997; 18: 54–9. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Mason B J, Goodman A M, Dixon R M, et al, A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology. 2002; 27: 596–606. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Johnson B A, O'Malley S S, Ciraulo D A, et al, Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J Clin Psychopharmacol. 2003; 23: 281–93. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kiefer F, Jahn H, Tarnaske T, et al, Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003; 60: 92–9. [PUBMED], [INFOTRIEVE], [CSA]
- Fuller R K, Branchey L, Brightwell D R, et al, Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA. 1986; 256: 1449–55. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Chick J, Gough K, Falkowski W, et al, Disulfiram treatment of alcoholism. Br J Psychiatry. 1992; 161: 84–9. [PUBMED], [INFOTRIEVE]
- Johnson B A, Ait-Daoud N, Bowden C L, et al, Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003; 361: 1677–85. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Mueller T I, Stout R L, Rudden S, et al, A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res. 1997; 21: 86–92. [PUBMED], [INFOTRIEVE], [CSA]
- Brady K T, Myrick H, Henderson S, Coffey S F. The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend. 2002; 67: 323–30. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Addolorato G, Caputo F, Capristo E, et al, Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002; 37: 504–8. [PUBMED], [INFOTRIEVE]
- Gorelick D A, Paredes A. Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res. 1992; 16: 261–5. [PUBMED], [INFOTRIEVE]
- Kranzler H R, Burleson J A, Brown J, Babor T F. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res. 1996; 20: 1534–41. [PUBMED], [INFOTRIEVE], [CSA]
- Naranjo C A, Sellers E M, Roach C A, Woodley D V, Sanchez-Craig M, Sykora K. Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers. Clin Pharmacol Ther. 1984; 35: 374–81. [PUBMED], [INFOTRIEVE]
- Naranjo C A, Sellers E M, Sullivan J T, Woodley D V, Kadlec K, Sykora K. The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther. 1987; 41: 266–74. [PUBMED], [INFOTRIEVE]
- Naranjo C A, Sullivan J T, Kadlec K E, Woodley-Remus D V, Kennedy G, Sellers E M. Differential effects of viqualine on alcohol intake and other consummatory behaviors. Clin Pharmacol Ther. 1989; 46: 301–9. [PUBMED], [INFOTRIEVE]
- Naranjo C A, Kadlec K E, Sanhueza P, Woodley-Remus D, Sellers E M. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther. 1990; 47: 490–8. [PUBMED], [INFOTRIEVE]
- Naranjo C A, Poulos C X, Bremner K E, Lanctot K L. Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers. Clin Pharmacol Ther. 1992; 51: 729–39. [PUBMED], [INFOTRIEVE]
- Kranzler H R, Burleson J A, Korner P, et al, Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry. 1995; 152: 391–7. [PUBMED], [INFOTRIEVE]
- Kabel D I, Petty F. A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol Clin Exp Res. 1996; 20: 780–4. [PUBMED], [INFOTRIEVE], [CSA]
- Pettinati H M, Volpicelli J R, Luck G, Kranzler H R, Rukstalis M R, Cnaan A. Double-blind clinical trial of sertraline treatment for alcohol dependence. J Clin Psychopharmacol. 2001; 21: 143–53. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pettinati H M, Volpicelli J R, Kranzler H R, Luck G, Rukstalis M R, Cnaan A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res. 2000; 24: 1041–9. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Johnson B A, Roache J D, Javors M A, et al, Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA. 2000; 284: 963–71. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Johnson B A, Jasinski D R, Galloway G P, et al, Ritanserin in the treatment of alcohol dependence—a multi-center clinical trial. Ritanserin Study Group. Psychopharmacology. 1996; 128: 206–15. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wiesbeck G A, Weijers H G, Chick J, Naranjo C A, Boening J. Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Ritanserin in Alcoholism Work Group. Alcohol Clin Exp Res. 1999; 23: 230–5
- Malec E, Malec T, Gagne M A, Dongier M. Buspirone in the treatment of alcohol dependence: a placebo-controlled trial. Alcohol Clin Exp Res. 1996; 20: 307–12. [PUBMED], [INFOTRIEVE], [CSA]
- Kline N S, Wren J C, Cooper T B, Varga E, Canal O. Evaluation of lithium therapy in chronic and periodic alcoholism. Am J Med Sci. 1974; 268: 15–22. [PUBMED], [INFOTRIEVE]
- Merry J, Reynolds C M, Bailey J, Coppen A. Prophylactic treatment of alcoholism by lithium carbonate. A controlled study. Lancet. 1976; 1: 481–2
- Pond S M, Becker C E, Vandervoort R, Phillips M, Bowler R M, Peck C C. An evaluation of the effects of lithium in the treatment of chronic alcoholism. I. Clinical results. Alcohol Clin Exp Res. 1981; 5: 247–51
- Fawcett J, Clark D C, Gibbons R D, et al, Evaluation of lithium therapy for alcoholism. J Clin Psychiatry. 1984; 45: 494–9. [PUBMED], [INFOTRIEVE]
- Fawcett J, Clark D C, Aagesen C A, et al, A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism. Arch Gen Psychiatry. 1987; 44: 248–56. [PUBMED], [INFOTRIEVE]
- Dorus W, Ostrow D G, Anton R, et al, Lithium treatment of depressed and nondepressed alcoholics. JAMA. 1989; 262: 1646–52. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bruno F. Buspirone in the treatment of alcoholic patients. Psychopathology. 1989; 22, (suppl 1). 49–59. [PUBMED], [INFOTRIEVE]
- Altamura A C, Mauri M C, Girardi T, Panetta B. Alcoholism and depression: a placebo controlled study with viloxazine. Int J Clin Pharmacol Res. 1990; 10: 293–8. [PUBMED], [INFOTRIEVE]
- Tollefson G D, Lancaster S P, Montague-Clouse J. The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency. Psychopharmacol Bull. 1991; 27: 163–70. [PUBMED], [INFOTRIEVE]
- Malcolm R, Anton R F, Randall C L, Johnston A, Brady K, Thevos A. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res. 1992; 16: 1007–13. [PUBMED], [INFOTRIEVE]
- Kranzler H R, Burleson J A, Del, Boca F K, et al, Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Arch Gen Psychiatry. 1994; 51: 720–31. [PUBMED], [INFOTRIEVE], [CSA]
- Mason B J, Kocsis J H, Ritvo E C, Cutler R B. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA. 1996; 275: 761–7. [PUBMED], [INFOTRIEVE], [CROSSREF]
- McGrath P J, Nunes E V, Stewart J W, et al, Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry. 1996; 53: 232–40. [PUBMED], [INFOTRIEVE], [CSA]
- Cornelius J R, Salloum I M, Ehler J G, et al, Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997; 54: 700–5. [PUBMED], [INFOTRIEVE], [CSA]
- Roy A. Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biol Psychiatry. 1998; 44: 633–7. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Roy-Byrne P P, Pages K P, Russo J E, et al, Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2000; 20: 129–36. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Randall C L, Johnson M R, Thevos A K, et al, Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety. 2001; 14: 255–62. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Moak D H, Anton R F, Latham P K, Voronin K E, Waid R L, Durazo-Arvizu R.. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. J Clin Psychopharmacol. 2003; 23: 553–62. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Helzer J E, Pryzbeck T R. The co-occurrence of alcoholism with other psychiatric disorders in the general population and its impact on treatment. J Stud Alcohol. 1988; 49: 219–24. [PUBMED], [INFOTRIEVE]
- Schuckit M A, Tipp J E, Bucholz K K, et al, The life-time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls. Addiction. 1997; 92: 1289–304. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Schneider U, Altmann A, Baumann M, et al, Comorbid anxiety and affective disorder in alcohol-dependent patients seeking treatment: the first Multicentre Study in Germany. Alcohol Alcohol. 2001; 36: 219–23. [PUBMED], [INFOTRIEVE]
- Schade A, Marquenie L A, Van Balkom A J, De, Beurs E, Van Dyck R, Van Den, Brink W. Do comorbid anxiety disorders in alcohol-dependent patients need specific treatment to prevent relapse?. Alcohol Alcohol. 2003; 38: 255–62. [PUBMED], [INFOTRIEVE]
- Schubiner H, Tzelepis A, Milberger S, et al, Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry. 2000; 61: 244–51. [PUBMED], [INFOTRIEVE]
- Clure C, Brady K T, Saladin M E, Johnson D, Waid R, Rittenbury M. Attention-deficit/hyperactivity disorder and substance use: symptom pattern and drug choice. Am J Drug Alcohol Abuse. 1999; 25: 441–8. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cornelius J R, Salloum I M, Thase M E, et al, Fluoxetine versus placebo in depressed alcoholic cocaine abusers. Psychopharmacol Bull. 1998; 34: 117–21. [PUBMED], [INFOTRIEVE], [CSA]
- Carroll K M, Nich C, Ball S A, McCance E, Rounsavile B J. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction. 1998; 93: 713–27. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Group TCSR, Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. Alcohol Clin Exp Res. 2003; 27: 1107–22. [CROSSREF], [CSA]